VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects aged 12-65                                │ Subjects aged 12-65                                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Confirmed idiopathic pulmonary hypertension,       │ Confirmed idiopathic pulmonary hypertension,       │     100 │
│ connective tissue disease associated pulmonary     │ connective tissue disease associated pulmonary     │         │
│ hypertension, congenital heart disease(with        │ hypertension, congenital heart disease(with        │         │
│ Eisenmenger syndrome) associated pulmonary         │ Eisenmenger syndrome) associated pulmonary         │         │
│ hypertension                                       │ hypertension                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Baseline 6-minutes walking distance 150m-550m      │ Baseline 6-minutes walking distance 150m-550m      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ WHO pulmonary hypertension function II-III with    │ WHO pulmonary hypertension function II-III with    │     100 │
│ non-responder to calcium channel blockers          │ non-responder to calcium channel blockers          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documented written informed consent                │ Documented written informed consent                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The other types of pulmonary hypertension          │ The other types of pulmonary hypertension          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who refuse to subscribe written informed  │ Subjects who refuse to subscribe written informed  │     100 │
│ consents or can't cooperate with the trial well    │ consents or can't cooperate with the trial well    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with serious acute or chronic disease     │ Subjects with serious acute or chronic disease     │     100 │
│ involved liver, kidney, and brain or have to use   │ involved liver, kidney, and brain or have to use   │         │
│ potent CYP3A4-inhibitor or nitrate to treat the    │ potent CYP3A4-inhibitor or nitrate to treat the    │         │
│ underlying diseases                                │ underlying diseases                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who are currently treated with sildenafil │ Subjects who are currently treated with sildenafil │     100 │
│ for PAH or taking sildenafil or tadalafil          │ for PAH or taking sildenafil or tadalafil          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other contraindications in package insert          │ Other contraindications in package insert          │     100 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                             │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════╪═════════╡
│ Must have maximum age of 65 Years │ Subjects aged 12-65                       │      35 │
├───────────────────────────────────┼───────────────────────────────────────────┼─────────┤
│ Must have minimum age of 12 Years │ Other contraindications in package insert │      38 │
╘═══════════════════════════════════╧═══════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 96
Average Levenshtein Ratio of individual lines: 89.41666666666667
OverAll Ratio: 92.70833333333334
